<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656121</url>
  </required_header>
  <id_info>
    <org_study_id>PCO</org_study_id>
    <nct_id>NCT02656121</nct_id>
  </id_info>
  <brief_title>Does Vitamin D Break the Vicious Circle of Polycystic Ovarian Syndrome of Insuline Resistance ?</brief_title>
  <acronym>PCOSD</acronym>
  <official_title>Advances in Pathogenesis and Management of Polycystic Ovarian Syndrome in Arab Girls and Women: Role of Vitamin D Status, Adipokines, Follistatin, and Vitamin D Supplementation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a special emphasis has recently been directed to the potential role of vitamin D
      and some regulatory peptides (e.g. adipokines and follistatin) and their associated metabolic
      roles and genetic factors in the development of PCOS and its related co-morbidities. The aim
      of this study is to compare the effect of vitamin D supplementation therapy and Metformin
      therapy on plasma concentrations of adipokines (ghrelin, resistin and adiponectin),
      follistatin and activins in participants diagnosed with PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question:

      In PCOS patients, is there any effect of vitamin D supplementation therapy on plasma
      concentrations of adipokines (ghrelin, resistin and adiponectin), follistatin and activins?

      Research hypothesis:

      There is a significant effect of vitamin D supplementation therapy on plasma concentrations
      of adipokines (ghrelin, resistin and adiponectin), follistatin and activin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>resumption of regular cycles</measure>
    <time_frame>6 months</time_frame>
    <description>cycles become regular</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>6 months</time_frame>
    <description>detection of fetal heart activity detected by transvaginal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration levels of adipokines</measure>
    <time_frame>6 months</time_frame>
    <description>(ghrelin, resistin and adiponectin), follistatin and activins in participants diagnosed with PCOS after vitamin D supplementation therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st subgroup will be treated with vitamin D together with standard treatment of PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2nd subgroup will be treated with standard anti-PCOS drug therapy and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>One-Alpha Capsules 0.25 microgram One-Alpha Capsules 0.5 microgram One-Alpha Capsules 1 microgram</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>one alpha, alfacalcidol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo instead of vitamin D</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed PCOS cases according to the National Institute of Health criteria (NIH
             consensus criteria) and Rotterdam criteria

        Exclusion Criteria:

          -  1- PCOS patients not in child bearing age; less than 18 years or more than 45 years.

             2- Patients with congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's
             syndrome, hyperprolactinemia and virilizing ovarian or adrenal tumors.

             3- PCOS patients with any other medical illness. 4- PCOS patients already on vitamin D
             supplements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M kotb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed M Kotb, MD</last_name>
    <phone>010086819990</phone>
    <phone_ext>0020</phone_ext>
    <email>ahmedmkotp@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ahmed M kotb, MD</last_name>
    <phone>1008681999</phone>
    <phone_ext>0020</phone_ext>
    <email>ahmedmkotp@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed kotb, MD</last_name>
      <phone>2001008681999</phone>
      <email>ahmedmkotp@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ahmed kotb</last_name>
      <email>ahmedmkotp@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>February 14, 2016</last_update_submitted>
  <last_update_submitted_qc>February 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed El Kotb Abdel Fattah</investigator_full_name>
    <investigator_title>Dr. Ahmed Kotb</investigator_title>
  </responsible_party>
  <keyword>PCOS, vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

